(Health Korea News / Changyong Lee) The Korea Pharmaceutical and Biotechnology Association held the 2nd AI New Drug Development Advisory Committee in 2024 at the Parnas Hotel in Gangnam-gu, Seoul on the 19th.
This meeting was held under the theme of ‘Nurturing experts in AI new drug development and building an innovation ecosystem.’ The results of the ‘AI-based new drug development education and promotion project’ so far were shared, and consultations and discussions were held on ▲ plans to advance human resource training and education ▲ and ▲ revitalization of AI use throughout the entire process of new drug development.
On this day, the advisory committee members agreed that based on the currently operating education platform LAIDD (Lectures on AI-driven Drug Discovery), there is a need to upgrade the AI transformation education system to meet the education needs of executive level, team leader level, and practical experts in pharmaceutical and bio companies. .
In particular, the advisory committee members emphasized the importance of interactive exchange between instructors and trainees and advised, “In addition to existing online lectures, in-depth paid lectures and research field consulting training appear to be additionally needed.”
Next, an in-depth discussion was held on ‘Establishing an innovation ecosystem for AI new drug development’. Advisory committee members emphasized that it is urgent for biopharmaceutical companies, hospitals, and AI technology companies to create success stories through public-private cooperation projects aimed at developing treatments for specific diseases. By carrying out collaborative tasks, it is possible to achieve breakthroughs in data utilization, develop new AI technologies, and spread AI new drug development at the same time.
“As a major task in building an innovative ecosystem for AI new drug development, we plan to carry out the ‘AI utilization technology development project in the clinical stage’ and the ‘precision new drug data hub project’,” said Ki Won-hee, vice president of the AI New Drug Convergence Research Institute. “We are planning specific implementation plans for this.” “We will continue to serve as a hub that connects supply and demand for AI new drug development.”
The association has been operating LAIDD since 2021 as part of the ‘Artificial Intelligence-Using New Drug Development Education and Promotion Project’ of the Ministry of Health and Welfare and the Korea Health Industry Development Institute. Currently, the number of new subscribers is 2,798, and the number of graduates is 462 (as of November 18), and a total of 150 talents have been trained through ‘Mentoring Project’ and ‘Boot Camp’, offline education linked to LAIDD.
Meanwhile, Noh Yeon-hong, president of the Korea Pharmaceutical and Biotechnology Association, said before the advisory committee, “The potential for AI application in the pharmaceutical bio sector is endless, and to realize this, technological convergence, cooperation between specialized areas, and education to understand each other are essential.” “We hope you will continue to contribute to speeding up digital transformation and AI new drug development.”
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
